Alkermes Demonstrates Proof of Concept for Orexin Receptor Agonist in ADHD

Alkermes (ALKS) has demonstrated proof of concept (PoC) in a Phase 1 clinical trial for adults with Attention Deficit Hyperactivity Disorder (ADHD) using its oral orexin-2 receptor (OX2R) agonist ALKS 7290, which is under development. After 14 days of administration, Adult ADHD Symptom Assessment Scale (AISRS) scores decreased by 14 points in the 20mg group and 19 points in the 50mg group, demonstrating dose-dependent and clinically significant symptom improvement. As a first-in-class mechanism targeting the orexin pathway that regulates arousal and attention, it is drawing attention for its potential to overcome the abuse risks and side effects characteristic of existing amphetamine-based CNS stimulants. Phase 2 results are expected in 2027, and the company faces the challenge of proving its unique position in the $16 billion ADHD treatment market dominated by low-cost generics.

Cue Biopharma's Phase 2 Success and Irrational Stock Drop

Cue Biopharma (CUE) announced that its anti-IgE monoclonal antibody CUE-221 (UB-221) met primary and key secondary endpoints in a Chinese Phase 2 trial involving 145 patients with chronic spontaneous urticaria (CSU). CUE-221 features a dual-action mechanism that not only neutralizes free IgE but also inhibits new IgE production, demonstrating superior urticaria symptom clearance and safety compared to placebo at the 12-week mark. However, immediately following the positive topline data announcement, the stock price plummeted due to heavy selling in the Nasdaq market, which Wall Street analysts have evaluated as an unfounded decline without any impairment to the company's intrinsic value. The company plans to accelerate entry into global Phase 2b/3 trials for regulatory approval based on its differentiated profile compared to the existing blockbuster Xolair.

AbbVie and Iambic Therapeutics Partnership for AI-based Multi-target Drug Discovery

AbbVie (ABBV) has entered into a multi-year strategic partnership with AI-based biotech Iambic Therapeutics for the discovery of small molecule compounds in the fields of immunology, neuroscience, and oncology. The strategy aims to significantly shorten the drug candidate discovery period by integrating Iambic's generative AI protein-binding prediction models, NeuralPLexer and Enchant v3. This deal reflects the trend of big pharma strategically internalizing technology to overcome the R&D limitations of traditional high-throughput screening (HTS) and reduce discovery costs. AbbVie is driving the expansion of its innovative drug (first-in-class) and best-in-class pipelines by integrating them with its proprietary data integration platform, ARCH.

Eli Lilly's FDA Approval for Expanded Indication of Oral SERD Combination Therapy

Eli Lilly and Company (LLY) has received full FDA approval for the combination therapy of Inluriyo (generic name: imlunestrant), an oral selective estrogen receptor degrader (SERD), and Verzenio (generic name: abemaciclib), a CDK4/6 inhibitor. The approval targets adult patients with ER+/HER2-, ESR1-mutated locally advanced or metastatic breast cancer that has progressed following previous endocrine therapy. In the pivotal Phase 3 trial EMBER-3, the combination therapy group achieved a median progression-free survival (mPFS) of 11.1 months compared to 5.5 months in the monotherapy group, significantly reducing the risk of disease progression by more than twofold. By maximizing patient convenience through a fully oral combination, the company is strengthening its market dominance against competing pipelines such as Menarini's Orserdu.